PTPN11 and juvenile myelomonocytic leukemia: Activating PTPN11 somatic mutations are the most common genetic drivers of JMML, accounting for approximately 35–40% of the patients (Figure 2), and are associated with an aggressive clinical course and poor disease outcome [10,11,12].